BridgeBio Pharma (BBIO)
(Delayed Data from NSDQ)
$26.74 USD
-0.09 (-0.34%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $26.72 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BBIO 26.74 -0.09(-0.34%)
Will BBIO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BBIO
BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down
BBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
Other News for BBIO
First Week of January 2027 Options Trading For BridgeBio Pharma (BBIO)
BridgeBio achondroplasia asset infigratinib nabs FDA Breakthrough Therapy status
BioMarin in spotlight as data suggests Ascendisâ???? candidate could rival Voxzogo
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
BioMarin price target lowered by $28 at Truist, here's why